Mosaic Therapeutics In-Licenses ASTX029 & ASTX295 from Astex Pharmaceuticals for Combination Therapy Development for Oncology
Shots:
- Mosaic has in-licensed ASTX029 & ASTX295 from Astex (Otsuka Pharmaceutical’s subsidiary) to develop combination therapies using these assets, with the 1st combination study expected to begin in 2026
- As per the deal, Astex granted Mosaic exclusive rights to develop combination products for pts with limited therapy options, receiving a 19% equity stake upfront & additional 3% based on clinical milestones along with potential future revenue shares; other financial terms remain undisclosed
- ASTX029 (ERK1/2 inhibitor), discovered by Astex & evaluated in a P-II trial, while ASTX295 (MDM2 antagonist) developed with Cancer Research UK’s Drug Discovery Unit at Newcastle University & was assessed in a P-I trial, both showing favorable safety in >100 pts each
Ref: Businesswire | Image: Mosaic Therapeutics & Astex Pharmaceutical
Related News:- Repertoire Immune Medicines Collaborates with Genentech to Develop T cell-Targeted Therapies for an Autoimmune Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
